BackSophiris Bio Overview

Sophiris Bio Current Cash

Sophiris Bio's current cash is $4.3M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$4.25M
↓ 64.72% YoYΔ $-7.80M vs prior year quarter

Peer average

Loading

Sophiris Bio Current Cash History

Loading

Sophiris Bio vs. peers: Current Cash Comparison

Loading

Sophiris Bio Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Sophiris Bio (SPHS) FAQ

Sophiris Bio (SPHS) currently reports a current cash of $4.3M as of September 2019. That compares with $12M in the prior-year period — down 64.7% year over year. Use the charts on this page to explore Sophiris Bio's current cash history and peer comparisons.

Sophiris Bio's current cash decreased from $12M to $4.3M — a 64.7% year-over-year decrease (period ending September 2019). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sophiris Bio reported $4.3M in current cash as of September 2019. That compares with $12M in the prior-year period — down 64.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $4.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sophiris Bio, and consider following SPHS for alerts when major investors trade the stock.

Sophiris Bio is classified in the Healthcare sector. On current cash, it currently shows $4.3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPHS with unrelated industries.